<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39377592</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2045-7634</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Cancer medicine</Title><ISOAbbreviation>Cancer Med</ISOAbbreviation></Journal><ArticleTitle>Evaluation of the safety of PD-1/PD-L1 inhibitors for immunotherapy in patients with malignant tumors after COVID-19 infection: A single-center cohort study.</ArticleTitle><Pagination><StartPage>e70202</StartPage><MedlinePgn>e70202</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70202</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/cam4.70202</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">An increasing body of evidence suggests a close association between COVID-19 infection and the safety of PD-1/PD-L1 inhibitor therapy in cancer patients. However, the available data concerning these impacts remain limited and occasionally contradictory.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">We conducted a retrospective analysis of cancer patients who received PD-1/PD-L1 inhibitor therapy at the same institution from November 2022 to May 2023. After excluding patients with missing information, a total of 224 cases were included. In our study, immune-related adverse events (irAEs) that occurred during the hospitalization of patients were included in the analysis. Further analysis of inter-subgroup differences was conducted following a 1:2 propensity score matching. Statistical analyses were performed using the Fisher's exact, chi-squared, and Mann-Whitney U-tests.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">The results showed that no statistically significant differences between the two subgroups in the incidence of irAEs, changes in immune function before and after using PD-1/PD-L1 inhibitors, and alterations in hepatic and renal function (p &gt; 0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings suggest that infection with COVID-19 does not significantly impact the safety of PD-1/PD-L1 inhibitors in cancer patients. Most cancer patients used PD-1/PD-L1 inhibitors during COVID-19 infection (asymptomatic or mild infection) did not experience exacerbation of their underlying condition, nor did they exhibit a substantial increase in toxic side effects.</AbstractText><CopyrightInformation>© 2024 The Author(s). Cancer Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Kaili</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, the 2nd Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Jinting</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yujie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The 1st Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Beining</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Queen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Oncology, the 2nd Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wenyige</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Queen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Xinyi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Yihui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The 2nd Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Daixin</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ai</LastName><ForeName>Kun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Queen Mary College, Jiangxi Medical College, Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yuchen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The 1st Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Long</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-5372-071X</Identifier><AffiliationInfo><Affiliation>Department of Oncology, the 2nd Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81960571</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>81960468</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Med</MedlineTA><NlmUniqueID>101595310</NlmUniqueID><ISSNLinking>2045-7634</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D060890">B7-H1 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C423236">CD274 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C105992">PDCD1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000082082" MajorTopicYN="Y">Immune Checkpoint Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060890" MajorTopicYN="N">B7-H1 Antigen</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19 infection</Keyword><Keyword MajorTopicYN="N">PD‐1/PD‐L1 inhibitor</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">immune‐related adverse events</Keyword><Keyword MajorTopicYN="N">propensity score matching</Keyword></KeywordList><CoiStatement>There are no conflicts of interest in this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>9</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39377592</ArticleId><ArticleId IdType="pmc">PMC11459677</ArticleId><ArticleId IdType="doi">10.1002/cam4.70202</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z. PD‐1/PD‐L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol. 2021;12:731798. doi:10.3389/fphar.2021.731798</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.731798</ArticleId><ArticleId IdType="pmc">PMC8440961</ArticleId><ArticleId IdType="pubmed">34539412</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD‐1/PD‐L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28. doi:10.1186/s12943-021-01489-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-021-01489-2</ArticleId><ArticleId IdType="pmc">PMC8780712</ArticleId><ArticleId IdType="pubmed">35062949</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Zhong Y, Peng S, Zhou X, Gan X. Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with pretreated advanced non‐small‐cell lung cancer: a meta‐analysis. Onco Targets Ther. 2018;11:8623‐8632. doi:10.2147/OTT.S181413</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S181413</ArticleId><ArticleId IdType="pmc">PMC6284541</ArticleId><ArticleId IdType="pubmed">30584321</ArticleId></ArticleIdList></Reference><Reference><Citation>Messina C, Salati M, Messina M, Cattrini C, Merz V, Caffo O. Efficacy and safety of PD1/PDL1 blockade with platinum‐based chemotherapy for extensive small cell lung cancer: a pooled analysis of randomized trials. Eur J Clin Investig. 2021;51(5):e13483. doi:10.1111/eci.13483</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13483</ArticleId><ArticleId IdType="pubmed">33382454</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Han J, Yang Y, Chen Y. PD‐1/PD‐L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol. 2022; 13(13):1070961. doi:10.3389/fimmu.2022.1070961</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1070961</ArticleId><ArticleId IdType="pmc">PMC9806143</ArticleId><ArticleId IdType="pubmed">36601120</ArticleId></ArticleIdList></Reference><Reference><Citation>Loretelli C, Abdelsalam A, D'Addio F, et al. PD‐1 blockade counteracts post‐COVID‐19 immune abnormalities and stimulates the anti‐SARS‐CoV‐2 immune response. JCI Insight. 2021;6(24):e146701. doi:10.1172/jci.insight.146701</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.146701</ArticleId><ArticleId IdType="pmc">PMC8783674</ArticleId><ArticleId IdType="pubmed">34784300</ArticleId></ArticleIdList></Reference><Reference><Citation>R Bonam S, Hu H, Bayry J. Role of the PD‐1 and PD‐L1 axis in COVID‐19. Future Microbiol. 2022;17:985‐988. doi:10.2217/fmb-2022-0103</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb-2022-0103</ArticleId><ArticleId IdType="pmc">PMC9332906</ArticleId><ArticleId IdType="pubmed">35899493</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbatino F, Conti V, Franci G, et al. PD‐L1 dysregulation in COVID‐19 patients. Front Immunol. 2021;12:695242. doi:10.3389/fimmu.2021.695242</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.695242</ArticleId><ArticleId IdType="pmc">PMC8215357</ArticleId><ArticleId IdType="pubmed">34163490</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh N, Tirpack A, Chan KK, Bass AR. Impact of COVID‐19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey. J Immunother Cancer. 2020;8(2):e001550. doi:10.1136/jitc-2020-001550</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2020-001550</ArticleId><ArticleId IdType="pmc">PMC7569707</ArticleId><ArticleId IdType="pubmed">33067320</ArticleId></ArticleIdList></Reference><Reference><Citation>Ottaviano M, Curvietto M, Rescigno P, et al. Impact of COVID‐19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. J Immunother Cancer. 2020;8(2):e001154. doi:10.1136/jitc-2020-001154</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2020-001154</ArticleId><ArticleId IdType="pmc">PMC7565202</ArticleId><ArticleId IdType="pubmed">33060148</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo M, Liu J, Miao R, et al. A single center retrospective study of the impact of COVID‐19 infection on immune‐related adverse events in cancer patients receiving immune checkpoint inhibitors. J Immunother. 2022;45(9):389‐395. doi:10.1097/CJI.0000000000000440</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CJI.0000000000000440</ArticleId><ArticleId IdType="pmc">PMC9528807</ArticleId><ArticleId IdType="pubmed">36066505</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Rizvi H, Egger JV, Preeshagul IR, Wolchok JD, Hellmann MD. Impact of PD‐1 blockade on severity of COVID‐19 in patients with lung cancers. Cancer Discov. 2020;10(8):1121‐1128. doi:10.1158/2159-8290.CD-20-0596</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-20-0596</ArticleId><ArticleId IdType="pmc">PMC7416461</ArticleId><ArticleId IdType="pubmed">32398243</ArticleId></ArticleIdList></Reference><Reference><Citation>Boussiotis VA. Molecular and biochemical aspects of the PD‐1 checkpoint pathway. N Engl J Med. 2016;375(18):1767‐1778. doi:10.1056/NEJMra1514296</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1514296</ArticleId><ArticleId IdType="pmc">PMC5575761</ArticleId><ArticleId IdType="pubmed">27806234</ArticleId></ArticleIdList></Reference><Reference><Citation>Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti‐PD‐L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558‐562. doi:10.1038/nature13904</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13904</ArticleId><ArticleId IdType="pubmed">25428503</ArticleId></ArticleIdList></Reference><Reference><Citation>Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single‐agent anti‐programmed death‐1 (MDX‐1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167‐3175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4834717</ArticleId><ArticleId IdType="pubmed">20516446</ArticleId></ArticleIdList></Reference><Reference><Citation>Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti‐PD‐1 antibody in cancer. N Engl J Med. 2012;366:2443‐2454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3544539</ArticleId><ArticleId IdType="pubmed">22658127</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao B, Zhao H, Zhao J. Fatal adverse events associated with programmed cell death protein 1 or programmed cell death‐ligand 1 monotherapy in cancer. Ther Adv Med Oncol. 2020;12:1758835919895753. doi:10.1177/1758835919895753</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1758835919895753</ArticleId><ArticleId IdType="pmc">PMC7005982</ArticleId><ArticleId IdType="pubmed">32082425</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang LF, Di Y, Xu XH, et al. Adverse effects of PD‐1/PD‐L1 blocker immunotherapy and their management principles. Chin J Drug Appl Monit. 2017;14(3):177.</Citation></Reference><Reference><Citation>Zhang JY, Wang XM, Xing X, et al. Single‐cell landscape of immunological responses in patients with COVID‐19. Nat Immunol. 2020;21(9):1107‐1118. doi:10.1038/s41590-020-0762-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0762-x</ArticleId><ArticleId IdType="pubmed">32788748</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen DY, Huang WK, Chien‐Chia WV, et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a review when cardiology meets immuno‐oncology. J Formos Med Assoc. 2020;119(10):1461‐1475. doi:10.1016/j.jfma.2019.07.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jfma.2019.07.025</ArticleId><ArticleId IdType="pubmed">31444018</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel L, Helfrich I, Hendgen‐Cotta UB, et al. Targeting early stages of cardiotoxicity from anti‐PD1 immune checkpoint inhibitor therapy. Eur Heart J. 2022;43(4):316‐329. doi:10.1093/eurheartj/ehab430</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab430</ArticleId><ArticleId IdType="pubmed">34389849</ArticleId></ArticleIdList></Reference><Reference><Citation>Staffa SJ, Zurakowski D. Five steps to successfully implement and evaluate propensity score matching in clinical research studies. Anesth Analg. 2018;127(4):1066‐1073. doi:10.1213/ANE.0000000000002787</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0000000000002787</ArticleId><ArticleId IdType="pubmed">29324498</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury E, Nevitt S, Madsen WR, Turtle L, Davies G, Palmieri C. Differences in outcomes and factors associated with mortality among patients with SARS‐CoV‐2 infection and cancer compared with those without cancer: a systematic review and meta‐analysis. JAMA Netw Open. 2022;5(5):e2210880. doi:10.1001/jamanetworkopen.2022.10880</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.10880</ArticleId><ArticleId IdType="pmc">PMC9086843</ArticleId><ArticleId IdType="pubmed">35532936</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS‐CoV‐2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39(8):1031‐1033. doi:10.1016/j.ccell.2021.07.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2021.07.012</ArticleId><ArticleId IdType="pmc">PMC8295014</ArticleId><ArticleId IdType="pubmed">34331856</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>